NovoCure
NASDAQ: NVCRFounded 2000 · 1,504 employees on LinkedIn · 2 known investors
Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
Founders & leadership
WF
William F. DoyleExecutive Chairman
FL
Frank LeonardinChief Executive Officer
Investors · 2
Competitors · 2
by search overlap
Onkure Therapeutics Inc41 shared keywordsOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
NextCure37 shared keywordsNextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
Companies competing with NovoCure for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
What’s Behind NovoCure (NVCR) Shares Climbing Today? - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does NovoCure do?
- Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer. The company focuses on patient-centered innovation in oncology.
- Who are NovoCure's investors?
- NovoCure's investors include Pfizer Venture Investments, Windham Capital Partners.